NZ584827A - Antisense modulation of fibroblast growth factor receptor 4 expression - Google Patents
Antisense modulation of fibroblast growth factor receptor 4 expressionInfo
- Publication number
- NZ584827A NZ584827A NZ584827A NZ58482708A NZ584827A NZ 584827 A NZ584827 A NZ 584827A NZ 584827 A NZ584827 A NZ 584827A NZ 58482708 A NZ58482708 A NZ 58482708A NZ 584827 A NZ584827 A NZ 584827A
- Authority
- NZ
- New Zealand
- Prior art keywords
- growth factor
- factor receptor
- fibroblast growth
- expression
- antisense modulation
- Prior art date
Links
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 title abstract 6
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 title abstract 6
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97678207P | 2007-10-01 | 2007-10-01 | |
| PCT/US2008/078497 WO2009046141A2 (en) | 2007-10-01 | 2008-10-01 | Antisense modulation of fibroblast growth factor receptor 4 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ584827A true NZ584827A (en) | 2012-10-26 |
Family
ID=40526946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ584827A NZ584827A (en) | 2007-10-01 | 2008-10-01 | Antisense modulation of fibroblast growth factor receptor 4 expression |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8486904B2 (enExample) |
| EP (1) | EP2215102B1 (enExample) |
| JP (1) | JP5792955B2 (enExample) |
| KR (1) | KR101660989B1 (enExample) |
| CN (1) | CN101883777B (enExample) |
| AU (1) | AU2008308691B2 (enExample) |
| BR (1) | BRPI0817527A2 (enExample) |
| CA (1) | CA2701128A1 (enExample) |
| IL (1) | IL204796A (enExample) |
| MX (1) | MX2010003606A (enExample) |
| NZ (1) | NZ584827A (enExample) |
| RU (1) | RU2501803C2 (enExample) |
| WO (1) | WO2009046141A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101660989B1 (ko) | 2007-10-01 | 2016-09-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절 |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| CA2758927A1 (en) * | 2009-04-15 | 2010-10-21 | Isis Pharmaceuticals, Inc. | Modulation of inflammatory responses by factor xi |
| US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| AU2012242642A1 (en) * | 2011-04-13 | 2013-05-02 | Ionis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| AU2012271357A1 (en) | 2011-06-16 | 2013-05-02 | Ionis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| RU2014105311A (ru) | 2011-07-19 | 2015-08-27 | Уэйв Лайф Сайенсес Пте. Лтд. | Способы синтеза функционализованных нуклеиновых кислот |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102337247B (zh) * | 2011-09-13 | 2013-07-10 | 西安交通大学 | 一种fgfr4高表达的重组hek293细胞及其应用 |
| EP3176170B1 (en) | 2012-06-13 | 2018-11-14 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| KR102712879B1 (ko) | 2012-07-13 | 2024-10-04 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PT2872485T (pt) | 2012-07-13 | 2021-03-05 | Wave Life Sciences Ltd | Grupo auxiliar assimétrico |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| JP6452614B2 (ja) | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2951305B1 (en) | 2013-01-30 | 2018-08-15 | F.Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| EP3119888B1 (en) * | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
| ES2812099T3 (es) | 2014-05-01 | 2021-03-16 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP4092119A3 (en) * | 2015-07-10 | 2023-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| US20190002887A1 (en) | 2015-12-31 | 2019-01-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing ataxin-2 expression |
| US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20240498A (es) | 2018-05-04 | 2025-01-08 | Incyte Corp | FORMAS SÓLIDAS DE UN INHIBIDOR DE FGFR Y PROCESOS PARA PREPARARLAS (Divisional EXP. 2020-0590) |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| AU2019310097A1 (en) | 2018-07-25 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ATXN2 expression |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0420081A1 (en) | 1989-09-26 | 1991-04-03 | Takeda Chemical Industries, Ltd. | Monoclonal antibody against an acidic FGF protein, its production and use |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20040006005A1 (en) * | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| EP0677055A1 (en) * | 1992-12-31 | 1995-10-18 | Texas Biotechnology Corporation | Antisense molecules directed against a fibroflast growth factor receptor gene family |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US20050053976A1 (en) | 1996-06-06 | 2005-03-10 | Baker Brenda F. | Chimeric oligomeric compounds and their use in gene modulation |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| DE69900847T2 (de) | 1998-04-17 | 2002-09-12 | Tufts College | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
| US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
| CA2373990C (en) | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| ES2264929T3 (es) | 1999-09-08 | 2007-02-01 | Genentech, Inc. | Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad. |
| AU2631001A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf11 |
| US6261840B1 (en) * | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6159734A (en) * | 2000-01-18 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| JP2003527858A (ja) | 2000-03-22 | 2003-09-24 | アムジェン インコーポレイテッド | 線維芽細胞増殖因子レセプター様分子およびその使用 |
| US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| IL152785A0 (en) | 2000-05-12 | 2003-06-24 | Univ Utah Res Found | Compositions and methods for cell dedifferentiation and tissue regeneration |
| EP1202065A1 (en) | 2000-10-25 | 2002-05-02 | Aventis Pharma S.A. | Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| DE10152147A1 (de) | 2001-10-25 | 2003-05-15 | Chemogenix Gmbh | Verfahren zum Aufbringen von Nukleosiden und/oder Nukleotiden auf funktionalisierten Oberflächen sowie Verfahren zur Bestimmung von Kopplungsausbeuten bei der Synthese von Nukleotiden |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| US7655397B2 (en) * | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| NZ537155A (en) | 2002-05-23 | 2006-09-29 | Cytopia Pty Ltd | Protein kinase inhibitors |
| TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| JP2005535629A (ja) * | 2002-06-27 | 2005-11-24 | ザ ユニバーシティ オブ クイーンズランド | 分化調節薬剤およびその使用法 |
| WO2004006005A1 (en) | 2002-07-08 | 2004-01-15 | Koninklijke Philips Electronics N.V. | Reflective stereoscopic display |
| JP2006513159A (ja) | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
| EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| US7803781B2 (en) * | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20050048494A1 (en) | 2003-08-28 | 2005-03-03 | Yixin Wang | Colorectal cancer prognostics |
| SI1680140T1 (sl) * | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
| EP1697420A2 (en) * | 2003-12-19 | 2006-09-06 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| CN101052644A (zh) | 2004-02-05 | 2007-10-10 | 因特拉迪格姆公司 | 治疗眼新生血管化疾病的RNAi治疗药物 |
| WO2005076999A2 (en) * | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Methods and compositions for combination rnai therapeutics |
| US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
| JP2008506366A (ja) * | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
| AU2005295756B2 (en) | 2004-10-13 | 2012-02-02 | Isis Parmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US20090299640A1 (en) * | 2005-11-23 | 2009-12-03 | University Of Utah Research Foundation | Methods and Compositions Involving Intrinsic Genes |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| KR101660989B1 (ko) | 2007-10-01 | 2016-09-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절 |
-
2008
- 2008-10-01 KR KR1020107009236A patent/KR101660989B1/ko not_active Expired - Fee Related
- 2008-10-01 CN CN200880118757.3A patent/CN101883777B/zh not_active Expired - Fee Related
- 2008-10-01 EP EP08835484.0A patent/EP2215102B1/en not_active Not-in-force
- 2008-10-01 WO PCT/US2008/078497 patent/WO2009046141A2/en not_active Ceased
- 2008-10-01 US US12/681,360 patent/US8486904B2/en not_active Expired - Fee Related
- 2008-10-01 CA CA2701128A patent/CA2701128A1/en not_active Abandoned
- 2008-10-01 BR BRPI0817527A patent/BRPI0817527A2/pt not_active IP Right Cessation
- 2008-10-01 MX MX2010003606A patent/MX2010003606A/es active IP Right Grant
- 2008-10-01 AU AU2008308691A patent/AU2008308691B2/en not_active Ceased
- 2008-10-01 RU RU2010116994/10A patent/RU2501803C2/ru not_active IP Right Cessation
- 2008-10-01 JP JP2010527254A patent/JP5792955B2/ja not_active Expired - Fee Related
- 2008-10-01 NZ NZ584827A patent/NZ584827A/xx not_active IP Right Cessation
-
2010
- 2010-03-28 IL IL204796A patent/IL204796A/en not_active IP Right Cessation
-
2013
- 2013-06-12 US US13/915,855 patent/US8895529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101883777A (zh) | 2010-11-10 |
| US8486904B2 (en) | 2013-07-16 |
| KR20100081994A (ko) | 2010-07-15 |
| AU2008308691B2 (en) | 2013-11-07 |
| WO2009046141A3 (en) | 2009-05-28 |
| CA2701128A1 (en) | 2009-04-09 |
| US20100292140A1 (en) | 2010-11-18 |
| JP2010539950A (ja) | 2010-12-24 |
| EP2215102B1 (en) | 2016-02-17 |
| JP5792955B2 (ja) | 2015-10-14 |
| US8895529B2 (en) | 2014-11-25 |
| AU2008308691A1 (en) | 2009-04-09 |
| EP2215102A2 (en) | 2010-08-11 |
| RU2010116994A (ru) | 2013-01-20 |
| IL204796A (en) | 2014-04-30 |
| CN101883777B (zh) | 2015-03-25 |
| IL204796A0 (en) | 2010-11-30 |
| EP2215102A4 (en) | 2012-04-11 |
| KR101660989B1 (ko) | 2016-09-28 |
| MX2010003606A (es) | 2010-07-02 |
| RU2501803C2 (ru) | 2013-12-20 |
| WO2009046141A2 (en) | 2009-04-09 |
| BRPI0817527A2 (pt) | 2017-05-02 |
| HK1146726A1 (zh) | 2011-07-08 |
| US20140080892A1 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ584827A (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
| ZA200803453B (en) | Modulation of glucagon receptor expression | |
| EA200800868A1 (ru) | Модуляция экспрессии глюкокортикоидного рецептора | |
| WO2004044181A3 (en) | Antisense modulation of apolipoprotein b expression | |
| WO2005049630A3 (en) | Antisense modulation of kinesin-like 1 expression | |
| WO2004071407A3 (en) | Antisense modulation of ptp1b expression | |
| TW200502385A (en) | Modulation of forkhead box o1a expression | |
| TW200519202A (en) | Modulation of eIF4E expression | |
| NZ624783A (en) | Modulation of huntingtin expression | |
| WO2004011610A3 (en) | Antisense modulation of polo-like kinase expression | |
| AU2009279857A8 (en) | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | |
| WO2004048534A3 (en) | Modulation of cytokine-inducible kinase expression | |
| WO2003052072A3 (en) | Antisense modulation of estrogen receptor alpha expression | |
| WO2005071080A3 (en) | Modulation of glucocorticoid receptor expression | |
| WO2003023004A3 (en) | Antisense modulation of fibroblast growth factor receptor 3 expression | |
| WO2004055162A3 (en) | Modulation of endothelial lipase expression | |
| EP1406915A4 (en) | ANTI-SENSE MODULATION OF BETA TYPE II TRANSFORMING GROWTH FACTOR RECEPTOR EXPRESSION | |
| WO2005014607A3 (en) | Antisense modulation of stearoyl-coa desaturase expression | |
| WO2004028458A3 (en) | Antisense modulation of microsomal prostaglandin e2 synthase expression | |
| WO2003104397A3 (en) | ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION | |
| WO2003050244A3 (en) | Antisense modulation of g protein-coupled receptor etbr-lp-2 expression | |
| WO2007062380A3 (en) | Modulation of eif4e-bp2 expression | |
| WO2005086804A3 (en) | Modulation of ace2 expression | |
| EP1572713A4 (en) | ANTISENSE MODULATION OF ACYL-COA SYNTHETASE 1 EXPRESSION | |
| WO2004014299A3 (en) | Antisense modulation of resistin expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 OCT 2015 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS Effective date: 20130522 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2016 BY CPA GLOBAL Effective date: 20150904 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 OCT 2017 BY CPA GLOBAL Effective date: 20160902 |
|
| LAPS | Patent lapsed |